Fiona Furlong

Phone+44 (0)28 9097 2296
Emailf.furlong@qub.ac.uk

Room 06.019 - Medical Biology Centre
United Kingdom

Accepting PhD Students

PhD projects

Open to PhD applications in the field of cancer research, cancer pharmacology, chemoresistance, cell and molecular biology, transcriptomics, biomarker development and drug discovery. Applications should meet the University's English language requirements, secured a source of funding, and who wish to pursue a research project in a relevant research topic. Exemplar PhD projects are detailed below: Mechanism of Drug activity in cancer https://www.dropbox.com/s/1r3f337i5m6mh32/PhD%20Studentship_HDAC6.pdf?dl=0 Molecular Pharmacology of GPCRs https://www.dropbox.com/s/04vjtc24i8svt3k/PhD%20Studentship_Neropeptide_galin.pdf?dl=0

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Interests

Receptor Pharmacology

Cancer Pharmacology

Mechanmis of Drug action

Cell Signalling

microRNA

Methylated RNA Biomarkers

Cancer Biology

Ovarian Cancer

Research Statement

I am a University College Dublin Graduate and joined the School of Pharmacy, QUB, as a Lecturer in Pharmacology and cancer researcher in 2012. Prior to joining QUB, I was a recipient of the Irish Cancer Society career development research fellowship in which I developed novel research on the role of the miR-433 microRNA as a biomarker of chemoresistance in ovarian cancer. My research focus is on cancer pharmacology and stratified biomarker development and I primarily research the mechanism of action of anti-neoplastic agents. Current projects include dissecting the molecular pharmacology of the histone deacetylase 6 (HDAC6) protein and the RNA demethylase enzymes. New and emerging research from my group is focused on developing methods to detect methylated microRNA as next generation biomarkers of disease. Areas of expertise include elucidating the mechanism of drug actions and downstream protein signalling in cell models of disease, cancer research and chemoresistance, cell and molecular biology, biomarker development and profiling microRNA in cells, tissue and plasma. My most significant research publications include studies of the miR-433 microRNA in chemoresistant ovarian cancer, IHC biomarker analyses and meta-analyse of the MAD2 protein in ovarian cancer prognosis. Research from my group has been funded by the Irish Cancer Society, the Health Research Board of Ireland, BBSRC and MRC.

Fingerprint Dive into the research topics where Fiona Furlong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

32 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

1 Finished
1 Active

R1565PMY: B vitamins and NAD metabolism, or when vitamin B3's bioavailability is not enough

Furlong, F.

25/09/2015 → …

Project: Research

R1818PMY: MRIs (Modified RNA Indicators): next generation gene signature biomarkers

Furlong, F. & Simpson, D.

16/10/2017 → 30/06/2019

Project: Research

Research Output

24 Article
11 Abstract
2 Poster
1 Review article

An update on Exosomes as Drug Delivery Vehicles: Obstacles to its Clinical Translation

Ali, A., Maguire, A. & Furlong, F., 02 Apr 2019, In : Novel Approaches in Drug Designing and Development. 5, 1, p. 0019

Research output: Contribution to journal › Review article

FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4

McClements, L., Annett, S., Yakkundi, A., O'Rourke, M., Valentine, A., Moustafa, N., Alqudah, A., Simões, B. M., Furlong, F., Short, A., McIntosh, S. A., McCarthy, H. O., Clarke, R. B. & Robson, T., 11 Apr 2019, In : BMC Cancer. 19, 351.

Research output: Contribution to journal › Article

Open Access

File

10 Citations (Scopus)

99 Downloads (Pure)

FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer

Annett, S., Moore, G., Short, A., Marshall, A., McCrudden, C., Yakkundi, A., Das, S., McCluggage, W. G., Nelson, L., Harley, I., Moustafa, N., Kennedy, C. J., deFazio, A., Brand, A., Sharma, R., Brennan, D., O'Toole, S., O'Leary, J., Bates, M., O'Riain, C. & 6 others, O'Connor, D., Furlong, F., McCarthy, H., Kissenpfennig, A., McClements, L. & Robson, T., 27 Nov 2019, In : British Journal of Cancer.

Research output: Contribution to journal › Article

Open Access

File

1 Citation (Scopus)

13 Downloads (Pure)

Too MAD or not MAD enough: The duplicitous role of the spindle assembly checkpoint protein MAD2 in cancer

Bates, M., Furlong, F., Gallagher, M. F., Spillane, C. D., McCann, A., O'Toole, S. & O'Leary, J. J., 05 Oct 2019, In : Cancer Letters. 469, p. 11-21 11 p.

Research output: Contribution to journal › Article